Efficacy and mode of action of mesalazine in the treatment of diarrhoea-predominant irritable bowel syndrome (IBS-D): Study protocol for a randomised controlled trial

Trials

Volumn 14, Issue 1, 2013, Pages

  Leighton, Matthew P ^a   Lam, Ching ^a   Mehta, Samir ^a   Spiller, Robin C ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

Diarrhoea predominant; Irritable bowel syndrome; Mesalazine

Indexed keywords

MESALAZINE; PLACEBO;

ABDOMINAL PAIN; ARTICLE; BLOATING; BLOOD SAMPLING; CONTROLLED STUDY; DEFECATION URGENCY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; FECES ANALYSIS; HUMAN; IRRITABLE COLON; MAJOR CLINICAL STUDY; MAST CELL; MULTICENTER STUDY; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; RECTUM BIOPSY; RECTUM MUCOSA; SIGMOIDOSCOPY; TREATMENT DURATION;

ABDOMINAL PAIN; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BIOPSY; CLINICAL PROTOCOLS; DEFECATION; DIARRHEA; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; ENGLAND; GASTROINTESTINAL AGENTS; HUMANS; IRRITABLE BOWEL SYNDROME; LINEAR MODELS; MAST CELLS; MESALAMINE; PATIENT SATISFACTION; QUESTIONNAIRES; RESEARCH DESIGN; TIME FACTORS; TREATMENT OUTCOME;

EID: 84872022385     PISSN: None     EISSN: 17456215     Source Type: Journal    
DOI: 10.1186/1745-6215-14-10     Document Type: Article

References (29)

1. Kroenke K. Physical symptom disorder: a simpler diagnostic category for somatization-spectrum conditions. J Psychosom Res 2006, 60:335-339. 10.1016/j.jpsychores.2006.01.022, 16581354.
2. Whitehead WE, Crowell MD, Robinson JC, Heller BR, Schuster MM. Effects of stressful life events on bowel symptoms: subjects with irritable bowel syndrome compared with subjects without bowel dysfunction. Gut 1992, 33:825-830. 10.1136/gut.33.6.825, 1379344, 1624167.
3. Santos J, Saperas E, Nogueiras C, Mourelle M, Antolin M, Cadahia A, Malagelada JR. Release of mast cell mediators into the jejunum by cold pain stress in humans. Gastroenterology 1998, 114:640-648. 10.1016/S0016-5085(98)70577-3, 9516384.
4. Guilarte M, Santos J, de Torres I, Alonso C, Vicario M, Ramos L, Martínez C, Casellas F, Saperas E, Malagelada JR. Diarrhoea-predominant IBS patients show mast cell activation and hyperplasia in the jejunum. Gut 2007, 56:203-209. 10.1136/gut.2006.100594, 1856785, 17005763.
5. Park JH, Rhee PL, Kim HS, Lee JH, Kim YH, Kim JJ, Rhee JC. Mucosal mast cell counts correlate with visceral hypersensitivity in patients with diarrhea predominant irritable bowel syndrome. J Gastroenterol Hepatol 2006, 21:71-78. 10.1111/j.1440-1746.2005.04143.x, 16706815.
6. Dunlop SP, Jenkins D, Spiller RC. Distinctive clinical, psychological, and histological features of postinfective irritable bowel syndrome. Am J Gastroenterol 2003, 98:1578-1583. 10.1111/j.1572-0241.2003.07542.x, 12873581.
7. Aron J. Response to mesalamine and balsalazide in patients with irritable bowel syndrome refractory to alosetron and tegaserod [abstract]. Gastroenterology 2005, 128:A329-A330.
8. Stefanini GF, Prati E, Albini MC, Piccinini G, Capelli S, Castelli E, Mazzetti M, Gasbarrini G. Oral disodium cromoglycate treatment on irritable bowel syndrome: an open study on 101 subjects with diarrheic type. Am J Gastroenterol 1992, 87:55-57.
9. Klooker TK, Braak B, Koopman KE, Welting O, Wouters MM, van der Heide S, Schemann M, Bischoff SC, van den Wijngaard RM, Boeckxstaens GE. The mast cell stabiliser ketotifen decreases visceral hypersensitivity and improves intestinal symptoms in patients with irritable bowel syndrome. Gut 2010, 59:1213-1221. 10.1136/gut.2010.213108, 20650926.
10. Dunlop SP, Jenkins D, Neal KR, Naesdal J, Borgaonker M, Collins SM, Spiller RC. Randomized, double-blind, placebo-controlled trial of prednisolone in post-infectious irritable bowel syndrome. Aliment Pharmacol Ther 2003, 18:77-84. 10.1046/j.1365-2036.2003.01640.x, 12848628.
11. Andrews CN, Petcu R, Griffiths T, Bjarnason J, Chapman K, Cellars L, Vergnolle N, Roux KP. Mesalamine alters colonic mucosal proteolytic activity and fecal bacterial profiles in diarrhea-predominant irritable bowel syndrome (IBS-D). Gastroenterology 2008, 134:A548-A.
12. Bafutto M, Almeida JR, Almeida RC, Almeida TC, Leite NV, Filho JR. Treatment of post-infectious irritable bowel syndrome and non infective irritable bowel syndrome with mesalazine [abstract]. Gastroenterology 2008, 134:A672.
13. Corinaldesi R, Stanghellini V, Cremon C, Gargano L, Cogliandro RF, De Giorgio R, Bartesaghi G, Canovi B, Barbara G. Effect of mesalazine on mucosal immune biomarkers in irritable bowel syndrome: a randomized controlled proof-of-concept study. Aliment Pharmacol Ther 2009, 30:245-252. 10.1111/j.1365-2036.2009.04041.x, 19438846.
14. Tuteja A, Hale D, Stoddard G, Fang J, Tolman K. Double-blind placebo controlled study of mesalamine in post-infective irritable bowel syndrome [abstract]. Am J Gastroenterol 2008, 103:S480.
15. Dunlop SP, Jenkins D, Neal KR, Spiller RC. Relative importance of enterochromaffin cell hyperplasia, anxiety, and depression in postinfectious IBS. Gastroenterology 2003, 125:1651-1659. 10.1053/j.gastro.2003.09.028, 14724817.
16. Gwee KA, Leong YL, Graham C, McKendrick MW, Collins SM, Walters SJ, Underwood JE, Read NW. The role of psychological and biological factors in postinfective gut dysfunction. Gut 1999, 44:400-406. 10.1136/gut.44.3.400, 1727402, 10026328.
17. Neal KR, Barker L, Spiller RC. Prognosis in post-infective irritable bowel syndrome: a six year follow up study. Gut 2002, 51:410-413. 10.1136/gut.51.3.410, 1773359, 12171965.
18. Chadwick VS, Chen W, Shu D, Paulus B, Bethwaite P, Tie A, Wilson I. Activation of the mucosal immune system in irritable bowel syndrome. Gastroenterology 2002, 122:1778-1783. 10.1053/gast.2002.33579, 12055584.
19. Liebregts T, Adam B, Bredack C, Roth A, Heinzel S, Lester S, Downie-Doyle S, Smith E, Drew P, Talley NJ, Holtmann G. Immune activation in patients with irritable bowel syndrome. Gastroenterology 2007, 132:913-920. 10.1053/j.gastro.2007.01.046, 17383420.
20. Dunlop SP, Hebden J, Campbell E, Naesdal J, Olbe L, Perkins AC, Spiller RC. Abnormal intestinal permeability in subgroups of diarrhea-predominant irritable bowel syndromes. Am J Gastroenterol 2006, 101:1288-1294. 10.1111/j.1572-0241.2006.00672.x, 16771951.
21. Spiller R, Garsed K. Postinfectious irritable bowel syndrome. Gastroenterology 2009, 136:1979-1988. 10.1053/j.gastro.2009.02.074, 19457422.
22. Fox CC, Moore WC, Lichtenstein LM. Modulation of mediator release from human intestinal mast cells by sulfasalazine and 5-aminosalicylic acid. Dig Dis Sci 1991, 36:179-184. 10.1007/BF01300753, 1703070.
23. Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC. Functional bowel disorders. Gastroenterology 2006, 130:1480-1491. 10.1053/j.gastro.2005.11.061, 16678561.
24. Lackner JM, Gudleski GD, Zack MM, Katz LA, Powell C, Krasner S, Holmes E, Dorscheimer K. Measuring health-related quality of life in patients with irritable bowel syndrome: can less be more?. Psychosom Med 2006, 68:312-320. 10.1097/01.psy.0000204897.25745.7c, 16554399.
25. Groll D, Vanner SJ, Depew WT, DaCosta LR, Simon JB, Groll A, Roblin N, Paterson WG. The IBS-36: a new quality of life measure for irritable bowel syndrome. Am J Gastroenterol 2002, 97:962-971. 10.1111/j.1572-0241.2002.05616.x, 12003433.
26. Bracco A, Jonsson B, Ricci JF, Drummond M, Nyhlin H. Economic evaluation of tegaserod vs. placebo in the treatment of patients with irritable bowel syndrome: an analysis of the TENOR study. Value Health 2007, 10:238-246. 10.1111/j.1524-4733.2007.00179.x, 17645678.
27. Hoad CL, Marciani L, Foley S, Totman JJ, Wright J, Bush D, Cox EF, Campbell E, Spiller RC, Gowland PA. Non-invasive quantification of small bowel water content by MRI: a validation study. Phys Med Biol 2007, 52:6909-6922. 10.1088/0031-9155/52/23/009, 18029983.
28. Marciani L, Cox EF, Hoad CL, Pritchard S, Totman JJ, Foley S, Mistry A, Evans S, Gowland PA, Spiller RC. Postprandial changes in small bowel water content in healthy subjects and patients with irritable bowel syndrome. Gastroenterology 2010, 138:469-477. 10.1053/j.gastro.2009.10.055, 19909743.
29. Arumugam M, Raes J, Pelletier E, Le Paslier D, Yamada T, Mende DR, Fernandes GR, Tap J, Bruls T, Batto JM, Bertalan M, Borruel N, Casellas F, Fernandez L, Gautier L, Hansen T, Hattori M, Hayashi T, Kleerebezem M, Kurokawa K, Leclerc M, Levenez F, Manichanh C, Nielsen HB, Nielsen T, Pons N, Poulain J, Qin J, Sicheritz-Ponten T, Tims S, et al. Enterotypes of the human gut microbiome. Nature 2011, 473:174-180. 10.1038/nature09944, 21508958.